Agilent director granted 3,215 shares in stock awards

AGILENT TECHNOLOGIES, INC. director George A. Scangos reported equity awards of common stock.

Accepted by SEC EDGAR 03/23/2026 - 04:29 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AGILENT TECHNOLOGIES, INC. director George A. Scangos reported equity awards of common stock. On 2026-03-19, he received two grants of Agilent common stock as a non-employee director, covering 2,158 shares and 1,057 shares at a reference price of $111.75 per share.

The awards are fully vested upon grant, and he has elected to defer receipt of these shares into a deferral account under Agilent’s 2005 Deferred Compensation Plan for Non-Employee Directors. A footnote also states that 148.973 shares were acquired through Agilent’s dividend reinvestment plan and likewise deferred.

After these transactions, Scangos holds 23,857.047 Agilent shares directly in deferred accounts and an additional 17,893 shares indirectly through the George A. Scangos and Leslie S. Wilson Family Trust. These transactions reflect compensation and deferral elections rather than open-market buying or selling.

Insider Trade Summary

Grant/Award: 3,215 shares

Grant/Award 2 txns

Insider SCANGOS GEORGE A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,158	$111.75	$241K
Grant/Award	Common Stock	1,057	$111.75	$118K
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 23,857.047 shares (Direct); Common Stock — 17,893 shares (Indirect, George A. Scangos and Leslie S. Wilson Family Trust)

Footnotes (4)

F1. Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock.
F2. 148.973 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.
F3. Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors.
F4. Shares held in the George A. Scangos and Leslie S. Wilson Family Trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Agilent (A) director George A. Scangos report in this Form 4?

He reported receiving two fully vested Agilent common stock awards as a non-employee director. The grants covered 2,158 and 1,057 shares, credited at $111.75 per share, and reflect compensation rather than open-market purchases or sales.

How many Agilent (A) shares did George Scangos acquire through awards and plans?

He received stock awards for 2,158 and 1,057 Agilent shares and a footnote notes 148.973 additional shares acquired through the company’s dividend reinvestment plan, all of which he elected to defer into a compensation deferral structure.

How many Agilent (A) shares does George Scangos hold after these transactions?

Following the reported awards, he holds 23,857.047 Agilent common shares directly in deferral accounts and 17,893 shares indirectly through the George A. Scangos and Leslie S. Wilson Family Trust, giving a combined reported position across direct and indirect holdings.

Were the Agilent (A) shares received by George Scangos immediately delivered or deferred?

The shares from the director stock awards are fully vested upon grant, but Scangos elected to defer receipt. They are held in a deferral account under Agilent’s 2005 Deferred Compensation Plan for Non-Employee Directors rather than being immediately delivered as tradable shares.

Does this Agilent (A) Form 4 show any open-market buying or selling by George Scangos?

No open-market purchases or sales are reported. The Form 4 reflects stock awards and dividend reinvestment credits treated as compensation, with the reporting person choosing to defer these shares instead of transacting in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCANGOS GEORGE A

(Last)

(First)

(Middle)

5301 STEVENS CREEK BLVD

(Street)

SANTA CLARA

CALIFORNIA

95051

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGILENT TECHNOLOGIES, INC. [ A ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/19/2026		A		2,158	A	$111.75⁽¹⁾	22,800.047⁽²⁾	D
Common Stock	03/19/2026		A		1,057⁽³⁾	A	$111.75	23,857.047	D
Common Stock								17,893	I	George A. Scangos and Leslie S. Wilson Family Trust⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock.

2. 148.973 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.

3. Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors.

4. Shares held in the George A. Scangos and Leslie S. Wilson Family Trust.

Remarks:

See Exhibit 24 - Power of Attorney

	/s/ Shirley Qin, attorney-in-fact for Dr. Scangos	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR